622
Participants
Start Date
December 31, 2016
Primary Completion Date
November 30, 2017
Study Completion Date
May 31, 2019
DFN-15 Active
DFN-15 Placebo
Site 705, Manhattan
Site 743, Williamsville
Site 746, Amherst
Site 717, Media
Site 731, Philadelphia
Site 712, Baltimore
Site 714, Virginia Beach
Site 715, Raleigh
Site 710, Anderson
Site 720, Decatur
Site 740, Blue Ridge
Site 721, Jacksonville
Site 735, DeLand
Site 711, Hialeah
Site 744, Birmingham
Site 724, Chattanooga
Site 728, Cincinnati
Site 707, Dayton
Site 734, West Des Moines
Site 704, Minneapolis
Site 736, Hazelwood
Site 737, Springfield
Site 739, Prairie Village
Site 713, Wichita
Site 706, Shreveport
Site 723, Little Rock
Site 718, Rogers
Site 701, Oklahoma City
Site 702, Plano
Site 719, Austin
Site 726, Colorado Springs
Site 727, Phoenix
Site 745, Las Vegas
Site 709, Los Angeles
Site 725, Santa Monica
Site 733, Upland
Site 729, San Diego
Site 708, Orange
Site 738, Simi Valley
Site 741, Salem
Site 722, Bellevue
Site 703, Boston
Site 730, New Bedford
Site 716, Berlin
Site 742, Lincoln
Lead Sponsor
BioDelivery Sciences International
INDUSTRY